<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515044</url>
  </required_header>
  <id_info>
    <org_study_id>RNHE2041</org_study_id>
    <nct_id>NCT03515044</nct_id>
  </id_info>
  <brief_title>Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)</brief_title>
  <acronym>OHE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets&#xD;
      Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the efficacy of rifaximin SSD plus lactulose&#xD;
      versus placebo plus lactulose for the treatment of overt hepatic encephalopathy (OHE). The&#xD;
      secondary objectives of this study are to assess the safety of rifaximin SSD in subjects with&#xD;
      OHE and to assess the effects of treatment with rifaximin SSD on key secondary endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2018</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinding will be maintained in the QD SSD cohorts by administering placebo as the second daily dose.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to OHE resolution determined using the Hepatic Encephalopathy Grading Instrument (HEGI).</measure>
    <time_frame>3 to 12 hours after administration</time_frame>
    <description>Major diagnostic criteria include: (1) disorientation (time, place, and/or person), or (2) presence of both lethargy and asterixis, or (3) coma. Inter- and intra-rater HEGI reproducibility</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Overt Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 40 mg Rifaximin SSD once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 40 mg Rifaximin SSD twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 80 mg Rifaximin SSD once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 80 mg Rifaximin SSD twice daiy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 80 mg Rifaximin SSD twice daily (BID) and lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Placebo twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSD placebo twice daily (BID) and lactulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg Rifaximin SSD once daily</intervention_name>
    <description>SSD once daily (QD) and lactulose</description>
    <arm_group_label>Cohort 1 40 mg Rifaximin SSD once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg Rifaximin SSD twice daily</intervention_name>
    <description>SSD twice daily (BID) and lactulose</description>
    <arm_group_label>Cohort 2 40 mg Rifaximin SSD twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg Rifaximin SSD once daily</intervention_name>
    <description>SSD once daily (QD) and lactulose</description>
    <arm_group_label>Cohort 3 80 mg Rifaximin SSD once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg Rifaximin SSD twice daily</intervention_name>
    <description>SSD twice daily (BID) and lactulose</description>
    <arm_group_label>Cohort 4 80 mg Rifaximin SSD twice daiy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered twice daily (BID) and lactulose</description>
    <arm_group_label>Cohort 5 Placebo twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactulose</intervention_name>
    <description>to be taken in the recommended adult size dosage.</description>
    <arm_group_label>Cohort 1 40 mg Rifaximin SSD once daily</arm_group_label>
    <arm_group_label>Cohort 2 40 mg Rifaximin SSD twice daily</arm_group_label>
    <arm_group_label>Cohort 3 80 mg Rifaximin SSD once daily</arm_group_label>
    <arm_group_label>Cohort 4 80 mg Rifaximin SSD twice daiy</arm_group_label>
    <arm_group_label>Cohort 5 Placebo twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age 18 to 75 years of age (inclusive) at the time of screening.&#xD;
&#xD;
          -  Females of childbearing potential, defined as a female who is fertile following&#xD;
             menarche, must have a negative serum pregnancy test at screening and agree to use an&#xD;
             acceptable method of contraception throughout their participation in the study.&#xD;
&#xD;
        Note: Female subjects who have been surgically sterilized (e.g., hysterectomy or bilateral&#xD;
        tubal ligation) or who are postmenopausal (defined as total cessation of menses for &gt; 1&#xD;
        year) will not be considered &quot;female subjects of childbearing potential&quot;.&#xD;
&#xD;
          -  Subject is hospitalized with liver cirrhosis and/or OHE and has a confirmed diagnosis&#xD;
             of OHE at Baseline.&#xD;
&#xD;
          -  Subject has a Grade 2 or Grade 3 HE episode according to the HE Grading Instrument&#xD;
             (HEGI) following 8 to 12 hours of intravenous (IV) hydration and lactulose treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has an uncontrolled major psychiatric disorder including major depression or&#xD;
             psychoses as determined by the investigator.&#xD;
&#xD;
          -  Subject has been diagnosed with an infection for which they are currently taking oral&#xD;
             or parenteral antibiotics, which cannot be discontinued at time of enrollment. Note:&#xD;
             Subjects currently taking Rifaximin are not excluded&#xD;
&#xD;
          -  Subject shows presence of intestinal obstruction or has inflammatory bowel disease.&#xD;
&#xD;
          -  Subject has uncontrolled Type 1 or Type 2 diabetes. Note: Subjects with controlled&#xD;
             diabetes may be enrolled if they are on stable doses of oral hypoglycemic drugs for at&#xD;
             least 3 months prior to screening, and demonstrate clinically acceptable blood glucose&#xD;
             control at Baseline, as determined by the investigator.&#xD;
&#xD;
          -  Subject has an active malignancy (exceptions: non-melanoma skin cancers).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Bulawski</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch Health Site 18</name>
      <address>
        <city>Corona Del Mar</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 15</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 19</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 04</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 13</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 08</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 05</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 33</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 03</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 07</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health 01</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 25</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 24</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 27</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 36</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 09</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 28</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 17</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 23</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 11</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 26</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 10</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 12</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 16</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 22</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 35</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 31</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 02</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 37</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 30</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 06</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 21</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 14</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bausch Health Site 20</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <disposition_first_submitted>March 10, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>March 10, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 11, 2021</disposition_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

